Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 356

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation: The COPPS-2 Randomized Clinical Trial

Open access
Imazio, Massimo, Brucato, Antonio, Ferrazzi, Paolo, Pullara, Alberto, Adler, Yehuda, Barosi, Alberto, Caforio, Alida L., Cemin, Roberto, Chirillo, Fabio, Comoglio, Chiara, Cugola, Diego, Cumetti, Davide, Dyrda, Oleksandr, Ferrua, Stefania, Finkelstein, Yaron, Flocco, Roberto, Gandino, Anna, Hoit, Brian, Innocente, Francesco, Maestroni, Silvia, Musumeci, Francesco, Oh, Jae, Pergolini, Amedeo, Polizzi, Vincenzo, Ristic, Arsen, Simon, Caterina, Spodick, David H, Tarzia, Vincenzo, Trimboli, Stefania, Valenti, Anna, Belli, Riccardo, Gaita, Fiorenzo·2014·JAMA

Abstract

IMPORTANCE: Postpericardiotomy syndrome, postoperative atrial fibrillation (AF), and postoperative effusions may be responsible for increased morbidity and health care costs after cardiac surgery. Postoperative use of colchicine prevented these complications in a single trial. OBJECTIVE: To determine the efficacy and safety of perioperative use of oral colchicine in reducing postpericardiotomy syndrome, postoperative AF, and postoperative pericardial or pleural effusions. DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, double-blind, placebo-controlled, randomized clinical trial among 360 consecutive candidates for cardiac surgery enrolled in 11 Italian centers between March 2012 and March 2014. At enrollment, mean age of the trial participants was 67.5 years (SD, 10.6 years), 69% were men, and 36% had planned valvular surgery. Main exclusion criteria were absence of sinus rhythm at enrollment, cardiac transplantation, and contraindications to colchicine. INTERVENTIONS: Patients were randomized to receive placebo (n=180) or colchicine (0.5 mg twice daily in patients ≥70 kg or 0.5 mg once daily in patients <70 kg; n=180) starting between 48 and 72 hours before surgery and continued for 1 month after surgery. MAIN OUTCOMES AND MEASURES: Occurrence of postpericardiotomy syndrome within 3 months; main secondary study end points were postoperative AF and pericardial or pleural effusion. RESULTS: The primary end point of postpericardiotomy syndrome occurred in 35 patients (19.4%) assigned to colchicine and in 53 (29.4%) assigned to placebo (absolute difference, 10.0%; 95% CI, 1.1%-18.7%; number needed to treat = 10). There were no significant differences between the colchicine and placebo groups for the secondary end points of postoperative AF (colchicine, 61 patients [33.9%]; placebo, 75 patients [41.7%]; absolute difference, 7.8%; 95% CI, -2.2% to 17.6%) or postoperative pericardial/pleural effusion (colchicine, 103 patients [57.2%]; placebo, 106 patients [58.9%]; absolute difference, 1.7%; 95% CI, -8.5% to 11.7%), although there was a reduction in postoperative AF in the prespecified on-treatment analysis (placebo, 61/148 patients [41.2%]; colchicine, 38/141 patients [27.0%]; absolute difference, 14.2%; 95% CI, 3.3%-24.7%). Adverse events occurred in 21 patients (11.7%) in the placebo group vs 36 (20.0%) in the colchicine group (absolute difference, 8.3%; 95% CI; 0.76%-15.9%; number needed to harm = 12), but discontinuation rates were similar. No serious adverse events were observed. CONCLUSIONS AND RELEVANCE: Among patients undergoing cardiac surgery, perioperative use of colchicine compared with placebo reduced the incidence of postpericardiotomy syndrome but not of postoperative AF or postoperative pericardial/pleural effusion. The increased risk of gastrointestinal adverse effects reduced the potential benefits of colchicine in this setting. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01552187.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2014.11026

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 356

Metadata

Authors
Imazio, M., Brucato, A., Ferrazzi, P., Pullara, A., Adler, Y., Barosi, A., Caforio, A. L., Cemin, R., Chirillo, F., Comoglio, C., Cugola, D., Cumetti, D., Dyrda, O., Ferrua, S., Finkelstein, Y., Flocco, R., Gandino, A., Hoit, B., Innocente, F., Maestroni, S., Musumeci, F., Oh, J., Pergolini, A., Polizzi, V., Ristic, A., Simon, C., Spodick, D. H., Tarzia, V., Trimboli, S., Valenti, A., Belli, R., & Gaita, F.
Venue
JAMA
Published
2014-09-10
Volume
312
Issue
10
Pages
1016
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2121523819
Cited by
356
References
17
FWCI
24.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation: The COPPS-2 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2014.11026
The paper
Imazio, M., Brucato, A., Ferrazzi, P., Pullara, A., Adler, Y., Barosi, A., Caforio, A. L., Cemin, R., Chirillo, F., Comoglio, C., Cugola, D., Cumetti, D., Dyrda, O., Ferrua, S., Finkelstein, Y., Flocco, R., Gandino, A., Hoit, B., Innocente, F., . . . Gaita, F. (2014). Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation: The COPPS-2 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2014.11026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.